Duyuru • Jul 08
OSR Health, Inc., Annual General Meeting, Aug 07, 2026 OSR Health, Inc., Annual General Meeting, Aug 07, 2026. Reported Earnings • May 14
First quarter 2026 earnings released: US$0.09 loss per share (vs US$1.05 loss in 1Q 2025) First quarter 2026 results: US$0.09 loss per share (improved from US$1.05 loss in 1Q 2025). Net loss: US$2.93m (loss narrowed 74% from 1Q 2025). Duyuru • May 12
OSR Holdings, Inc., Annual General Meeting, Jun 18, 2026 OSR Holdings, Inc., Annual General Meeting, Jun 18, 2026. Location: washington, seattle, United States New Risk • Apr 29
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Revenue has declined by 18% over the past year. Shareholders have been substantially diluted in the past year (72% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$37m net loss next year). Revenue is less than US$5m (US$2.9m revenue). Market cap is less than US$100m (US$24.7m market cap). Duyuru • Mar 10
OSR Holdings, Inc. Receives Additional Compliance Period to Regain Compliance with Nasdaq Listing Rule On March 5, 2026, OSR Holdings, Inc. (the Company) received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (Nasdaq) notifying the Company that Nasdaq has granted the Company an additional 180 calendar day period, or until August 31, 2026, to regain compliance with Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share. As previously disclosed, on September 5, 2025, the Company received notice from Nasdaq that the closing bid price of the Company's common stock had fallen below the required minimum bid price of $1.00 per share for 30 consecutive business days and that the Company had been provided an initial 180 calendar day compliance period, or until March 4, 2026, to regain compliance. Nasdaq determined that the Company is eligible for the additional compliance period because the Company meets the continued listing requirement for the market value of publicly held shares and all other applicable requirements for initial listing on the Nasdaq Capital Market, with the exception of the minimum bid price requirement. If at any time during this additional compliance period the closing bid price of the Company's common stock is at least $1.00 per share for a minimum of 10 consecutive business days, Nasdaq will provide written confirmation that the Company has regained compliance with the minimum bid price requirement. The Company intends to monitor the closing bid price of its common stock and will consider available options to regain compliance with Nasdaq's minimum bid price requirement. Board Change • Dec 31
High number of new and inexperienced directors There are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. 1 experienced director. No highly experienced directors. Chief Legal Officer & Director Jun Whang is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Duyuru • Sep 11
OSR Holdings, Inc. Receives A Written Notice from the Listing Qualifications Department of the Nasdaq Stock Market Regarding Minimum Bid Price Requirement On September 5, 2025, OSR Holdings, Inc. (the Company") received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (Nasdaq") indicating that the Company is not in compliance with the minimum bid price requirement set in Nasdaq Listing Rule 5550(a)(2), because the closing bid price of the Company's common stock has been below $1.00 per share for 30 consecutive business days. The notice has no immediate effect on the listing or trading of the Company's securities, which will continue to trade on The Nasdaq Capital Market under the symbols OSRH" and OSRHW." The Company has been provided an initial period of 180 calendar days, or until March 4, 2026, to regain compliance. If at any time during this period the closing bid price of the Company's common stock is at least $1.00 for a minimum of ten consecutive business days, Nasdaq will provide written confirmation that the Company has regained compliance. If the Company does not regain compliance by March 4, 2026, it may be eligible for an additional 180-day compliance period, provided that it meets the continued listing requirements for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market (other than the bid price requirement), and provides written notice to Nasdaq of its intent to cure the deficiency, including by means of a reverse stock split if necessary. If the Company is not eligible for the second compliance period, Nasdaq will provide notice that the Company's securities are subject to delisting, which determination the Company may appeal. The Company intends to actively monitor the closing bid price of its common stock and will consider available options to regain compliance with the Nasdaq Listing Rules. New Risk • Aug 26
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 31% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$1.8m free cash flow). Share price has been highly volatile over the past 3 months (31% average weekly change). Revenue has declined by 48% over the past year. Shareholders have been substantially diluted in the past year (434% increase in shares outstanding). Revenue is less than US$1m (US$105k revenue). Minor Risks Less than 3 years of financial data is available. Market cap is less than US$100m (US$11.1m market cap). Duyuru • Aug 20
OSR Holdings, Inc., Annual General Meeting, Sep 17, 2025 OSR Holdings, Inc., Annual General Meeting, Sep 17, 2025. Location: 5 penn plaza, 19th floor, new york 1001., new york United States Reported Earnings • Aug 19
Second quarter 2025 earnings released: EPS: US$0.02 (vs US$1.83 loss in 2Q 2024) Second quarter 2025 results: EPS: US$0.02 (up from US$1.83 loss in 2Q 2024). Net income: US$331.4k (up US$3.79m from 2Q 2024). Duyuru • Jul 02
OSR Holdings, Inc. Announces Resignation of Sang Hyun Kim as A Member of the Board of Directors OSR Holdings, Inc. announced that on June 26, 2025, Sang Hyun Kim provided notice of his resignation as a member of the Board of Directors, including his role as an independent director of the company. Mr. Kim’s resignation took immediate effect and was not the result of any dispute or disagreement with the Company on any matter relating to its operations, policies or practices. Duyuru • May 16
OSR Holdings, Inc. announced delayed 10-Q filing On 05/15/2025, OSR Holdings, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Duyuru • Apr 24
OSR Holdings, Inc. Auditor Raises 'Going Concern' Doubt OSR Holdings, Inc. filed its 10-K on Apr 22, 2025 for the period ending Dec 31, 2024. In this report its auditor, WithumSmith+Brown, PC , gave an unqualified opinion expressing doubt that the company can continue as a going concern. Duyuru • Apr 04
OSR Holdings, Inc. announced that it expects to receive $80 million in funding OSR Holdings, Inc. entered into purchase agreement to sell common stock up to gross proceeds $80,000,000 on April 3, 2025. The transaction includes participation from White Lion GBM Innovation Fund. Duyuru • Mar 25
OSR Holdings, Inc. Appoints Constance Höfer as Chief Scientific Officer OSR Holdings, Inc. announced the appointment of Dr. Constance Höfer as its new Chief Scientific Officer (CSO). Dr. Höfer, a seasoned leader in drug development with over 20 years of experience in oncology and immunology, will oversee OSR Holdings' scientific strategy and innovation pipeline. Dr. Höfer joins OSR Holdings from Merck Healthcare, where she led global programs spanning from preclinical to late-stage clinical development. Prior to Merck, she held senior leadership positions at Sandoz Biopharmaceuticals, Priaxon AG, and Medigene AG, playing a key role in advancing therapeutic programs across various modalities, including New Biological Entities (NBEs), New Chemical Entities (NCEs), nucleotides, and viral and cell-based therapies. Coupled with her extensive industry experience and a PhD in Pharmacology from the University of Newcastle, Dr. Höfer has a strong foundation in clinical pharmacology and translational medicine, ensuring a seamless transition from early-stage research to successful clinical development. Dr. Höfer's appointment reinforces OSR Holdings' commitment to advancing cutting-edge therapeutic solutions and strengthening its R&D capabilities. Her expertise will enhance the company's ability to identify and develop promising drug candidates, streamline clinical development, and improve regulatory success rates. By leveraging her experience in biologics, small molecules, and other advanced therapeutic modalities, OSR Holdings aims to accelerate the translation of innovative research into clinical applications, expand its footprint in oncology and immunology, and drive long-term value for both patients and stakeholders. 
